Acknowledgements: Muriel Herasse played a major role in collecting the missing data of the cohort.

We thank Julien Labreuche (biostatistician, CHU-Lille) for the help in the statistical analysis.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2021-eular.1092

OP0285

COVID-19 HOSPITALIZATIONS, ICU ADMISSION, AND DEATH AMONG PATIENTS WITH IMMUNE MEDIATED INFLAMMATORY DISEASES (IMID) – A POPULATION-BASED STUDY

L. Eder^{1,2}, R. Croxford³, A. Drucker^{2,4}, A. Mendel⁵, K. Bindee^{4,6}, Z. Touma^{4,7}, R. Cook⁸, S. Johnson^{4,7}, S. Bernatsky⁸, N. Haroon^{1,7}, J. Widdifield^{9,10}

¹University of Toronto, Medicine and Institute of Medical Science, Toronto, Canada; ²Women's College Research Institute, Medicine, Toronto, Canada;

³ICES, NA, Toronto, Canada; ⁴University of Toronto, Medicine and Health Policy Management and Evaluation, Toronto, Canada; ⁵McGill University,

Medicine, Montreal, Canada; ⁶Sinai Health System, Medicine, Toronto, Canada; ⁷Toronto Western Hospital, Medicine, Toronto, Canada; ⁸University of Waterloo,

Biostatistics, Waterloo, Canada; ⁹University of Toronto, Institute of Health Policy Management and Evaluation, Toronto, Canada; ¹⁰Sunnybrook Research Institute, Medicine, Toronto, Canada

Background: It remains unclear whether patients with IMID are at greater risk for severe COVID-19.

Objectives: To investigate the risk of COVID-19 hospitalizations and their outcomes in patients with IMID compared with matched non-IMID patients from the general population.

Methods: A population-based, matched cohort study was conducted in adults living in Ontario, Canada using health administrative data. Ten cohorts of the following IMID were assembled: rheumatoid arthritis, psoriasis, psoriatic arthritis, ankylosing spondylitis, systemic autoimmune rheumatic diseases (SARDs), including systemic lupus, systemic sclerosis, Sjogren's, myositis), multiple sclerosis (MS), iritis, inflammatory bowel disease, polymyalgia rheumatica (PMR), and vasculitis (including giant cell arteritis and other types of vasculitides). Each patient was matched with 5 non-IMID comparators based on age, sex, area of residence and living in long-term care (LTC). Patients who were admitted to hospital from January 1st to July 31st, 2020 and had ICD-10 COVID-19 diagnosis codes (U07.2 or U07.1) were identified. Among those with COVID-19 hospitalizations, we determined those with admissions to intensive care unit or required mechanical ventilation or died in hospital ('complicated hospitalization'). Age-sex-standardized rates were compared between IMID and non-IMID patients and risk factors for hospitalizations were identified by multivariable logistic regression analysis.

Results: In total, 493,499 IMID (417 hospitalized) and 2,466,946 non-IMID patients (1,519 hospitalized) were assessed. The age-sex-standardized rate of COVID-19 hospitalization was higher in IMID (6.4 per 10,000, 95% confidence interval (CI) 5.8, 7.2) versus non-IMID patients (4.8 per 100,000, 95% CI 4.5, 5). The highest rates of hospitalizations were found in vasculitis (18/10,000), MS (16.7/10,000) and PMR (10.1/10,000). IMID diagnosis was associated with 37% higher risk of being hospitalized for COVID-19 (Odds Ratio (OR) 1.37, 95% CI 1.23, 1.53) (Figure 1). This risk was slightly attenuated after adjusting for socio-demographic factors and comorbidities but remained elevated by 23% compared to non-IMID (OR 1.23, 95% CI 1.10, 1.37). The risk for hospitalizations was increased in RA, vasculitis, SARDs, PsA, MS and iritis (Figure 1). Risk factors for COVID-19 hospitalizations included older age, male sex, lower income, multimorbidity and living in long-term care (Table 1). The risk for complicated COVID-19 hospitalizations was higher by 21% in IMID patients (OR 1.21, 95% CI 1.02, 1.43), however, this association was attenuated after adjustment for demographics and comorbidities (OR 1.08).

Table 1. Risk Factors for COVID-19 Hospitalizations in IMIDs vs. non-IMIDs

Variable	OR	95% CI
IMIDs vs. Non-IMID	1.23	1.10, 1.37
Age (10 yrs)	1.49	1.44, 1.54
Sex: Female	0.68	0.62, 0.75
Long term care resident	8.28	7.32, 9.37
ADG: 5-9 vs. 0-4	1.45	1.22, 1.71
10-14 vs. 0-4	2.26	1.92, 2.67
15+ vs. 0-4	3.23	2.73, 3.82
Income (quintile)		
Quintile 2 vs. 1	0.82	0.73, 0.93
Quintile 3 vs. 1	0.76	0.67, 0.86
Quintile 4 vs. 1	0.56	0.48, 0.64
Quintile 5 vs. 1	0.46	0.40, 0.54
Urban vs. rural	4.33	3.32, 5.67

ADG - Aggregated Diagnosis Groups

Conclusion: Patients with IMID were at higher risk of being hospitalized with COVID-19 and for having complicated hospitalizations. Hospitalization risk was partially independent of their comorbid conditions.

Acknowledgements: The study is supported by ICES, which is funded by an annual grant from the Ontario Ministry of Health and Long-Term Care (MOHLTC). Parts of this material are based on data and information compiled and provided by MOHLTC and the Canadian Institute for Health Information. The opinions, results and conclusions reported in this paper are those of the authors and are independent of the funding or data sources; no endorsement is intended or should be inferred.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2021-eular.1466

OP0286

CHARACTERISTICS ASSOCIATED WITH SEVERE COVID-19 OUTCOMES IN SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): RESULTS FROM THE COVID-19 GLOBAL RHEUMATOLOGY ALLIANCE (COVID-19 GRA)

M. F. Ugarte-Gil^{1,2}, G. S. Alarcon^{3,4}, A. Seet⁵, Z. Izadi^{5,6}, C. Reategui Sokolova^{2,7}, A. E. Clarke⁸, L. Wise⁹, G. Pons-Estel¹⁰, M. J. Santos¹¹, S. Bernatsky¹², L. Mathias⁹, N. Lim⁹, J. Sparks¹³, Z. Wallace¹⁴, K. Hyrich¹⁵, A. Strangfeld¹⁶, L. Gossec¹⁷, L. Carmona¹⁸, E. Mateus¹⁹, S. Lawson-Tovey²⁰, L. Trupin⁵, S. Rush⁵, G. Schmajuk⁵, P. Katz⁵, L. Jacobsohn⁵, S. Al Emadi²¹, E. Gilbert²², A. Duarte-Garcia²³, M. Valenzuela-Almada²⁴, T. Hsu²⁵, K. D'Silva²⁶, N. Serling-Boyd²⁷, P. Dieudé²⁸, E. Nikiphorou²⁹, V. Kronzer³⁰, N. Singh³¹, B. Wallace³², A. Akpabio³³, R. Thomas³⁴, S. Bhana³⁵, W. Costello³⁶, R. Grainger³⁷, J. Hausmann³⁸, J. Liew³⁹, E. Siroitch⁴⁰, P. Sufka⁴¹, P. Robinson⁴², P. Machado⁴³, M. Gianfrancesco⁵, J. Yazdany⁴⁴ on behalf of COVID-19 Global Rheumatology Alliance. ¹Universidad Científica del Sur, School of Medicine, Lima, Peru; ²Hospital Nacional Guillermo Almenara Irigoyen, EsSalud, Rheumatology, Lima, Peru; ³University of Alabama at Birmingham, Department of Medicine, Birmingham, Alabama, United States of America; ⁴Universidad Peruana Cayetano Heredia, Facultad de Medicina, Lima, Peru; ⁵University of California, Division of Rheumatology, Department of Medicine, San Francisco, United States of America; ⁶University of California, Department of Epidemiology and Biostatistics, San Francisco, United States of America; ⁷Universidad San Ignacio de Loyola, Unidad de Investigación para la Generación y Síntesis de Evidencias en Salud, Lima, Peru; ⁸Cumming School of Medicine, University of Calgary, Division of Rheumatology Department of Medicine, Calgary, Canada; ⁹University of Southern California, Division of Rheumatology, Department of Internal Medicine, Los Angeles, CA, United States of America; ¹⁰Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Centro Regional de Enfermedades Autoinmunes y Reumáticas (GO-CREAR), Rosario, Argentina; ¹¹Instituto de Medicina Molecular, Faculdade de Lisboa, Rheumatology Department, Hospital Garcia de Orta, Almada and Rheumatology Research Unit, Lisbon, Portugal; ¹²McGill University Health Centre, Divisions of Rheumatology and Clinical Epidemiology,

Quebec, Canada; ¹³Brigham and Women's Hospital and Harvard Medical School, Division of Rheumatology, Inflammation, and Immunity, Boston, MA, United States of America; ¹⁴Massachusetts General Hospital, Harvard Medical School, Clinical Epidemiology Program and Rheumatology Unit, Division of Rheumatology, Allergy, and Immunology, Boston, MA, United States of America; ¹⁵The University of Manchester, Centre for Epidemiology Versus Arthritis, Manchester, United Kingdom; ¹⁶German Rheumatism Research Center (DRFZ Berlin), Epidemiology and Health Care Research, Berlin, Germany; ¹⁷Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France; ¹⁸Instituto de Salud Musculoesquelética, Instituto de Salud Musculoesquelética, Madrid, Spain; ¹⁹Portuguese League Against Rheumatic Diseases (LPCDR), Portuguese League Against Rheumatic Diseases (LPCDR), Lisbon, Portugal; ²⁰University of Manchester, Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, Manchester, United Kingdom; ²¹Hamad Medical Corporation, Rheumatology Department, Doha, Qatar; ²²Mayo Clinic, Division of Rheumatology, Jacksonville, Florida, United States of America; ²³Mayo Clinic, Division of Rheumatology and Robert D. and Patricia E. Kern Center for the Science of Health Care Delivery, Rochester, Minnesota, United States of America; ²⁴Mayo Clinic, Division of Rheumatology, Rochester, Minnesota, United States of America; ²⁵Brigham and Women's Hospital and Harvard Medical School, Division of Rheumatology, Inflammation, and Immunity, Boston, United States of America; ²⁶Massachusetts General Hospital, Harvard Medical School, Clinical Epidemiology Program and Rheumatology Unit, Division of Rheumatology, Allergy, and Immunology, Boston, United States of America; ²⁷Massachusetts General Hospital, Harvard Medical School, Rheumatology Unit, Division of Rheumatology, Allergy, and Immunology, Boston, United States of America; ²⁸Hôpital Bichat, Rheumatology, Paris, France; ²⁹Kings College London, Centre for Rheumatic Disease, London, United Kingdom; ³⁰Mayo Clinic, Rheumatology, Rochester, United States of America; ³¹University of Washington, Division of Rheumatology, Washington, United States of America; ³²University of Michigan, Department of Internal Medicine/Rheumatology, Michigan, United States of America; ³³University of Uno Teaching Hospital, Rheumatology, Uyo, Nigeria; ³⁴University of Queensland, UQ Diamantina Institute, Brisbane, Australia; ³⁵Crystal Run Health, Crystal Run Health, Middletown, NY, United States of America; ³⁶Irish Children's Arthritis Network (iCAN), Irish Children's Arthritis Network (iCAN), Ireland; ³⁷University of Otago, Department of Medicine, Wellington, New Zealand; ³⁸Beth Israel Deaconess Medical Center, Harvard Medical School, Program in Rheumatology, Boston Children's Hospital; Division of Rheumatology and Clinical Immunology, Boston, MA, United States of America; ³⁹Boston University School of Medicine, Section of Rheumatology, Department of Medicine, Boston, United States of America; ⁴⁰McMaster University, Department of Health Research Methods, Evidence, and Impact, Hamilton, ON, Canada; ⁴¹Healthpartners, St. Paul, MN, United States of America; ⁴²University of Queensland, Faculty of Medicine, Brisbane, United States of America; ⁴³University College London, Centre for Rheumatology & Department of Neuromuscular Diseases, London, United Kingdom; ⁴⁴University of California, Division of Rheumatology, Department of Medicine, San Francisco, United States of America

Background: An increased risk of severe COVID-19 outcomes may be seen in patients with autoimmune diseases on moderate to high daily doses of glucocorticoids, as well as in those with comorbidities. However, specific information about COVID-19 outcomes in SLE is scarce.

Objectives: To determine the characteristics associated with severe COVID-19 outcomes in a multi-national cross-sectional registry of COVID-19 patients with SLE.

Methods: SLE adult patients from a physician-reported registry of the COVID-19 GRA were studied. Variables collected at COVID-19 diagnosis included age, sex, race/ethnicity, region, comorbidities, disease activity, time period of COVID-19 diagnosis, glucocorticoid (GC) dose, and immunomodulatory therapy. Immunomodulatory therapy was categorized as: antimalarials only, no SLE therapy, traditional immunosuppressive (IS) drug monotherapy, biologics/targeted synthetic IS drug monotherapy, and biologic and traditional IS drug combination therapy. We used an ordinal COVID-19 severity outcome defined as: not hospitalized/hospitalized without supplementary oxygen; hospitalized with non-invasive ventilation; hospitalized with mechanical ventilation/extracorporeal membrane oxygenation; and death. An ordinal logistic regression model was constructed to assess the association between demographic characteristics, comorbidities, medications, disease activity and COVID-19 severity. This assumed that the relationship between each pair of outcome groups is of the same direction and magnitude.

Results: Of 1069 SLE patients included, 1047 (89.6%) were female, with a mean age of 44.5 (SD: 14.1) years. Patient outcomes included 815 (78.8%) not hospitalized/hospitalized without supplementary oxygen; 116 (11.2%) hospitalized with non-invasive ventilation, 25 (2.4%) hospitalized with mechanical ventilation/extracorporeal membrane oxygenation and 78 (7.5%) died. In a multivariate model (n=804), increased age [OR=1.03 (1.01, 1.04)], male sex [OR =1.93 (1.21,

3.08)], COVID-19 diagnosis between June 2020 and January 2021 [OR =1.87 (1.17, 3.00)], no IS drug use [OR =2.29 (1.34, 3.91)], chronic renal disease [OR =2.34 (1.48, 3.70)], cardiovascular disease [OR =1.93 (1.34, 3.91)] and moderate/high disease activity [OR =2.24 (1.46, 3.43)] were associated with more severe COVID-19 outcomes. Compared with no use of GC, patients using GC had a higher odds of poor outcome: 0-5 mg/d, OR =1.98 (1.33, 2.96); 5-10 mg/d, OR =2.88 (1.27, 6.56); >10 mg/d, OR =2.01 (1.26, 3.21) (Table 1).

Table 1. Characteristics associated with more severe COVID-19 outcomes in SLE. (N=804)

	OR (95% CI)
Age, years	1.03 (1.01, 1.04)
Sex, Male	1.93 (1.21, 3.08)
Race/Ethnicity, Non-White vs White	1.47 (0.87, 2.50)
Region	
Europe	Ref.
North America	0.67 (0.29, 1.54)
South America	0.67 (0.29, 1.54)
Other	1.93 (0.85, 4.39)
Season, June 16th 2020-January 8th 2021 vs January-June 15th 2020	1.87 (1.17, 3.00)
Glucocorticoids	
0 mg/day	Ref.
0-5 mg/day	1.98 (1.33, 2.96)
5-10 mg/day	2.88 (1.27, 6.56)
=>10 mg/day	2.01 (1.26, 3.21)
Medication Category	
Antimalarial only	Ref.
No IS drugs	2.29 (1.34, 3.91)
Traditional IS drugs as monotherapy	1.17 (0.77, 1.77)
b/ts IS drugs as monotherapy	1.00 (0.37, 2.71)
Combination of traditional and b/ts IS	1.00 (0.55, 1.82)
Comorbidity Burden	
Number of Comorbidities (excluding renal and cardiovascular disease)	1.39 (0.97, 1.99)
Chronic renal disease	2.34 (1.48, 3.70)
Cardiovascular disease	1.93 (1.34, 3.91)
Disease Activity, Moderate/ high vs Remission/ low	2.24 (1.46, 3.43)

IS: immunosuppressive. b/ts: biologics/targeted synthetics

Conclusion: Increased age, male sex, glucocorticoid use, chronic renal disease, cardiovascular disease and moderate/high disease activity at time of COVID-19 diagnosis were associated with more severe COVID-19 outcomes in SLE. Potential limitations include possible selection bias (physician reporting), the cross-sectional nature of the data, and the assumptions underlying the outcomes modelling.

Acknowledgements: The views expressed here are those of the authors and participating members of the COVID-19 Global Rheumatology Alliance and do not necessarily represent the views of the ACR, EULAR, the UK National Health Service, the National Institute for Health Research (NIHR), or the UK Department of Health, or any other organization.

Disclosure of Interests: Manuel F. Ugarte-Gil Grant/research support from: Pfizer, Janssen, Graciela S Alarcon: None declared, Andrea Seet: None declared, Zara Izadi: None declared, Cristina Reategui Sokolova: None declared, Ann E Clarke Consultant of: AstraZeneca, BristolMyersSquibb, GlaxoSmithKline, Exagen Diagnostics, Leanna Wise: None declared, Guillermo Pons-Estel: None declared, Maria Jose Santos: None declared, Sasha Bernatsky: None declared, Lauren Mathias: None declared, Nathan Lim: None declared, Jeffrey Sparks Consultant of: Bristol-Myers Squibb, Gilead, Inova, Janssen, and Optum unrelated to this work., Grant/research support from: Amgen and Bristol-Myers Squibb, Zachary Wallace Consultant of: Viela Bio and MedPace, Grant/research support from: Bristol-Myers Squibb and Principia/Sanofi, Kimme Hyrich Speakers bureau: Abbvie, Grant/research support from: MS, UCB, and Pfizer, Anja Strangfeld Speakers bureau: AbbVie, MSD, Roche, BMS, Pfizer, Grant/research support from: AbbVie, BMS, Celltrion, Fresenius Kabi, Lilly, Mylan, Hexal, MSD, Pfizer, Roche, Samsung, Sanofi-Aventis, and UCB, Laure Gossec Consultant of: Abbvie, Biogen, Celgene, Janssen, Lilly, Novartis, Pfizer, Sanofi-Aventis, UCB, Grant/research support from: Lilly, Mylan, Pfizer, Loreto Carmona: None declared, Elsa Mateus Grant/research support from: Pfizer, Abbvie, Novartis, Janssen-Cilag, Lilly Portugal, Sanofi, Grünenthal S.A., MSD, Celgene, Medac, Pharmakern, GafPA, Saskia Lawson-Tovey: None declared, Laura Trupin: None declared, Stephanie Rush: None declared, Gabriela Schmajuk: None declared, Patti Katz: None declared, Lindsay Jacobsohn: None declared, Samar Al Emadi: None declared, Emily Gilbert: None declared, Ali Duarte-Garcia: None declared, Maria Valenzuela-Almada: None declared, Tiffany Hsu: None declared, Kristin D'Silva: None declared, Naomi Serling-Boyd: None declared, Philippe Dieudé Consultant of: Boehringer Ingelheim, Bristol-Myers Squibb, Lilly, Sanofi, Pfizer, Chugai, Roche, Janssen unrelated to this work, Grant/research support from: Bristol-Myers Squibb, Chugai, Pfizer, unrelated to this work, Elena Nikiphorou: None declared, Vanessa Kronzer: None declared, Namrata Singh: None declared, Beth Wallace: None

declared, Akpabio Akpabio: None declared, Ranjeny Thomas: None declared, Suleman Bhana Consultant of: AbbVie, Horizon, Novartis, and Pfizer (all <\$10,000) unrelated to this work, Wendy Costello: None declared, Rebecca Grainger Speakers bureau: Abbvie, Janssen, Novartis, Pfizer, Cornerstones, Jonathan Hausmann Consultant of: Novartis, Sobi, Biogen, all unrelated to this work (<\$10,000), Jean Liew Grant/research support from: Pfizer outside the submitted work, Emily Sirotich Grant/research support from: Board Member of the Canadian Arthritis Patient Alliance, a patient run, volunteer based organization whose activities are largely supported by independent grants from pharmaceutical companies, Paul Sufka: None declared, Philip Robinson Speakers bureau: Abbvie, Eli Lilly, Janssen, Novartis, Pfizer and UCB (all <\$10,000), Consultant of: Abbvie, Eli Lilly, Janssen, Novartis, Pfizer and UCB (all <\$10,000), Pedro Machado Speakers bureau: Abbvie, BMS, Celgene, Eli Lilly, Janssen, MSD, Novartis, Pfizer, Roche and UCB, all unrelated to this study (all <\$10,000), Consultant of: Abbvie, BMS, Celgene, Eli Lilly, Janssen, MSD, Novartis, Pfizer, Roche and UCB, all unrelated to this study (all <\$10,000), Milena Gianfrancesco: None declared, Jinoos Yazdany Consultant of: Eli Lilly and AstraZeneca unrelated to this project
DOI: 10.1136/annrheumdis-2021-eular.2984

OP0287

IMMUNOMODULATORY THERAPIES FOR SEVERE FORMS OF COVID-19: A SYSTEMATIC LITERATURE REVIEW TO INFORM EULAR POINTS TO CONSIDER

A. Alunno¹, A. Najm², X. Mariette³, J. Emmel⁴, L. Mason⁴, G. De Marco⁵, D. McGonagle⁵, P. Machado⁶. ¹Rheumatology Unit, University of Perugia, Department of Medicine, Perugia, Italy; ²Institute of Infection, Immunity and Inflammation, University of Glasgow, College of Medical Veterinary and Life Sciences, Glasgow, United Kingdom; ³Paris-Saclay University, AP-HP, INSERM, Le Kremlin Bicêtre, France; ⁴Leeds Teaching Hospitals NHS Trust, Library & Evidence Research Centre, Medical Education, Leeds, United Kingdom; ⁵University of Leeds, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Leeds, United Kingdom; ⁶University College London, Centre for Rheumatology & Department of Neuromuscular Diseases, London, United Kingdom

Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV2) pandemic is a global health problem. Beside the specific pathogenic effect of SARS-CoV-2, a deleterious aberrant non-effective host immune response plays an important role especially in severe forms of COVID-19. There is intense investigation to explore the utility of immunomodulatory drugs commonly used in the Rheumatology arena as agents that may mitigate against COVID-19 to improve disease prognosis. Rheumatologists are used to the utilization of these immune targeted therapies.

Objectives: To summarize the available information on the use of immunomodulatory agents in severe COVID-19.

Methods: As part of a EULAR taskforce, a systematic literature search was conducted from January 2019 up to December 11, 2020. Two reviewers independently identified eligible studies according to the PICO framework P (population): patients with SARS-CoV-2 infection; I (intervention): any immunomodulator agent/strategy; C (comparator): any comparator; O (outcome) any clinical outcome including but not limited to mortality, admission to intensive care unit and clinical improvement. Data on efficacy and safety of immunomodulatory agents utilized therapeutically in SARS-CoV-2 infection at any stage were extracted. The risk of bias was assessed using validated tools.

Results: Of 60372 records, 401 articles were eligible for inclusion. Studies were at variable risk of bias. Randomised controlled trials (RCTs) were available for the following drugs: hydroxychloroquine (N=12), glucocorticoids (N=6), tocilizumab (N=4), convalescent plasma (N=4), interferon beta (N=2), IVIg (N=2) and N=1 each for anakinra, baricitinib, colchicine, leflunomide, ruxolitinib, interferon kappa, and vilobelimab. For glucocorticoids, dexamethasone reduced mortality only in patients requiring respiratory support; while methylprednisolone reduced mortality in patients aged 60 years or over. Data from RCTs on tocilizumab are conflicting and definite conclusions cannot be drawn at this point in time, but recent studies suggest possible benefit in patients requiring respiratory support. Hydroxychloroquine was not beneficial at any disease stage, one RCT with anakinra was negative, one RCT with baricitinib+remdesivir was positive, and individual trials testing some other compounds provided interesting, albeit preliminary, results.

Conclusion: Although there is emerging evidence about immunomodulatory therapies for the management of COVID-19, conclusive data is scarce with some conflicting data. Since glucocorticoids seem to improve survival in some subsets of patients, RCTs comparing glucocorticoids alone versus glucocorticoids plus anti-cytokine/immunomodulatory treatment are warranted. This SLR informed the initiative to formulate EULAR points to consider on pathophysiology and use of immunomodulatory therapies in COVID-19.

Figure 1. Forest plots showing the risk ratio (RR) and 95% confidence interval for mortality in randomized controlled trials divided by intervention. The latest follow-up available is reported in the timing column.

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2021-eular.3367

OP0288

MACHINE LEARNING ALGORITHMS TO PREDICT COVID-19 ACUTE RESPIRATORY DISTRESS SYNDROME IN PATIENTS WITH RHEUMATIC DISEASES: RESULTS FROM THE GLOBAL RHEUMATOLOGY ALLIANCE PROVIDER REGISTRY

Z. Izadi^{1,2}, M. Gianfrancesco², K. Hyrich^{3,4}, A. Strangfeld⁵, L. Gossec^{6,7}, L. Carmona⁸, E. Mateus^{9,10}, S. Lawson-Tovey^{4,11}, L. Trupin², S. Rush², G. Schmajuk^{2,12}, L. Jacobsohn², P. Katz², S. Al Emadi¹³, L. Wise¹⁴, E. Gilbert¹⁵, M. Valenzuela-Almada¹⁶, A. Duarte-Garcia¹⁵, J. Sparks¹⁷, T. Hsu¹⁷, K. D'Silva¹⁸, N. Serling-Boyd¹⁹, S. Bhana²⁰, W. Costello²¹, R. Grainger²², J. Hausmann^{23,24}, J. Liew²⁵, E. Sirotich^{26,27}, P. Sufka²⁸, Z. Wallace¹⁸, P. Machado^{29,30,31}, P. Robinson^{32,33}, J. Yazdany². ¹University of California, San Francisco, Department of Epidemiology and Biostatistics, San Francisco, United States of America; ²University of California, San Francisco, Division of Rheumatology, Department of Medicine, San Francisco, United States of America; ³The University of Manchester, Centre for Epidemiology Versus Arthritis, Manchester, United Kingdom; ⁴Manchester Academic Health Science Centre, National Institute of Health Research Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester, United Kingdom; ⁵German Rheumatism Research Center (DRFZ Berlin), Epidemiology and Health Care Research, Berlin, Germany; ⁶Sorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France; ⁷University Hospitals Pitié Salpêtrière - Charles Foix, Rheumatology, Paris, France; ⁸Instituto de Salud Musculoesquelética (InMusc), Department of Rheumatology, Madrid, Spain; ⁹Portuguese League Against Rheumatic Diseases (LPCDR), Rheumatology, Lisbon, Portugal; ¹⁰European League Against Rheumatism (EULAR) Standing Committee of People with Arthritis/Rheumatism in Europe (PARE), Rheumatology, Kilchberg, Switzerland; ¹¹University of Manchester, Centre for Genetics and Genomics Versus Arthritis, Centre for Musculoskeletal Research, Manchester, United Kingdom; ¹²San Francisco VA Healthcare System, Department of Rheumatology, San Francisco, United States of America; ¹³Hamad Medical Corporation, Rheumatology Department, Doha, Qatar; ¹⁴University of Southern California, Division of Rheumatology, Department of Internal Medicine, Los Angeles, United States of America; ¹⁵Mayo Clinic, Department of Rheumatology, Rochester, United